These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10491791)

  • 1. Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers.
    Marin MG; Van Lieu J; Yee A; Bonner E; Glied S
    J Occup Environ Med; 1999 Sep; 41(9):754-60. PubMed ID: 10491791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
    Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
    JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis.
    Stringer JS; Rouse DJ
    Obstet Gynecol; 1999 Jul; 94(1):34-40. PubMed ID: 10389714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
    Messori A; Becagli P; Berto V; Trippoli S; Font M; Tosolini F; Venturini F; Martini N
    Ann Pharmacother; 1997 Dec; 31(12):1447-54. PubMed ID: 9416379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in Northern Thailand.
    Thaineua V; Sirinirund P; Tanbanjong A; Lallemant M; Soucat A; Lamboray JL
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):429-42. PubMed ID: 10437936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on HIV chemoprophylaxis following exposure.
    Flaxman NA; Reed HS
    J Tenn Dent Assoc; 1997 Oct; 77(4):42-4. PubMed ID: 9520762
    [No Abstract]   [Full Text] [Related]  

  • 16. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia.
    Guinot D; Ho MT; Poynten IM; McAllister J; Pierce A; Pell C; Grulich AE
    HIV Med; 2009 Apr; 10(4):199-208. PubMed ID: 19207598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy.
    Myers ER; Thompson JW; Simpson K
    Obstet Gynecol; 1998 Feb; 91(2):174-81. PubMed ID: 9469271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers.
    Puro V; Francisci D; Sighinolfi L; Civljak R; Belfiori B; Deparis P; Roda R; Modestino R; Ghinelli F; Ippolito G
    J Hosp Infect; 2004 Jun; 57(2):179-82. PubMed ID: 15183251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.